Wells Fargo’s Immuneering IMRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$45.1K Sell
11,007
-35,697
-76% -$169K ﹤0.01% 5564
2026
Q2
$233K Buy
46,704
+29,904
+178% +$151K ﹤0.01% 5103
2026
Q1
$88.5K Buy
16,800
+1,800
+12% +$9.23K ﹤0.01% 5170
2025
Q4
$98.7K Hold
15,000
– – ﹤0.01% 5395
2025
Q3
$105K Buy
15,000
+5,000
+50% +$25.9K ﹤0.01% 5288
2025
Q2
$33.7K Buy
+10,000
New +$17.1K ﹤0.01% 5644
2024
Q2
– Sell
-6,974
Closed -$20.2K – 7156
2024
Q1
$20.2K Buy
6,974
+926
+15% +$5.19K ﹤0.01% 5573
2023
Q4
$44.5K Buy
6,048
+1,328
+28% +$8.85K ﹤0.01% 5320
2023
Q3
$36.2K Sell
4,720
-3,568
-43% -$32.8K ﹤0.01% 5347
2023
Q2
$84K Buy
8,288
+8,162
+6,478% +$78.5K ﹤0.01% 5145
2023
Q1
$1.22K Buy
126
+2
+2% +$11 ﹤0.01% 6322
2022
Q4
$601 Sell
124
-997
-89% -$8.83K ﹤0.01% 6333
2022
Q3
$16K Buy
1,121
+1,066
+1,938% +$8.46K ﹤0.01% 5504
2022
Q2
$0 Sell
55
-9,838
-99% -$52.5K ﹤0.01% 7116
2022
Q1
$64K Sell
9,893
-297
-3% -$2.85K ﹤0.01% 5535
2021
Q4
$165K Buy
10,190
+10,146
+23,059% +$247K ﹤0.01% 5373
2021
Q3
$1K Buy
+44
New +$1.18K ﹤0.01% 6719

Other funds holding IMRX

Wells Fargo's IMRX Position: Q3 2026 in Review

Wells Fargo reduced its Immuneering (IMRX) stake by 76% in Q3 2026, selling an estimated $169K and leaving 11,007 shares worth $45.1K. The position accounts for ﹤0.01% of the portfolio, ranked #5564.

Wells Fargo first reported a position in IMRX in Q3 2021 and has held it in 17 quarters since. The position peaked at $233K in Q2 2026. 127 funds tracked by Wall St. Rank hold IMRX as of Q3 2026.

  • Wells Fargo held 11,007 shares of Immuneering worth $45.1K as of Q3 2026.
  • Wells Fargo sold 35,697 Immuneering shares in Q3 2026, an estimated $169K.
  • Immuneering made up ﹤0.01% of Wells Fargo's portfolio in Q3 2026, its #5564 holding.
  • Wells Fargo first reported a position in Immuneering in Q3 2021 and has held it in 17 quarters since.
  • Wells Fargo's Immuneering position peaked at $233K in Q2 2026.
  • 127 funds tracked by Wall St. Rank held Immuneering as of Q3 2026.

Based on Wells Fargo's 13F filing for Q3 2026, filed 16 Nov 2026.